ライフサイエンスコーパス: acute graft-versus-host disease

1 showed similar incidences of grades II to IV acute graft-versus host disease.

2 cell source and donor type, age and grade of acute graft-versus-host disease.

3 53 patients (17%) developed grades II to IV acute graft-versus-host disease.

4 ently in the treatment of steroid-refractory acute graft-versus-host disease.

5 f the five children had grade II, III, or IV acute graft-versus-host disease.

6 patibility complex barriers without inducing acute graft-versus-host disease.

7 associated with a higher risk of developing acute graft-versus-host disease.

8 nd death (P = 0.002), but a similar risk for acute graft-versus-host disease.

9 ficantly increased risk of graft failure and acute graft versus host disease after URD BMT.

10 New-onset acute graft-versus-host disease after CAR T-cell infusio

11 There was no de novo acute graft-versus-host disease after infusion, and inci

12 with alphaCD154 Ab has been shown to prevent acute graft versus host disease (aGvHD).

13 (AT) was capable of protecting animals from acute graft-versus-host disease (aGVHD) across major his

14 R-181a expression in donor T cells may alter acute graft-versus-host disease (aGvHD) after allogeneic

15 Acute graft-versus-host disease (aGVHD) continues to be

16 e lower incidence and severity of high-grade acute graft-versus-host disease (aGVHD) exhibited by UCB

17 arly diagnosis, prevention, and treatment of acute graft-versus-host disease (aGVHD) have been transl

18 T cells have improved survival and decreased acute graft-versus-host disease (aGVHD) in 2 different m

19 During acute graft-versus-host disease (aGVHD) in mice, autorea

20 eg cells protects recipient mice from lethal acute graft-versus-host disease (aGVHD) induced by donor

21 ective therapy for hematologic malignancies, acute graft-versus-host disease (aGVHD) is a leading cau

22 Acute graft-versus-host disease (aGVHD) is a major cause

23 Steroid refractory gastrointestinal (GI) acute graft-versus-host disease (aGVHD) is a major cause

24 Acute graft-versus-host disease (aGVHD) is a major compl

25 Acute graft-versus-host disease (aGVHD) is associated wi

26 We found that acute graft-versus-host disease (aGVHD) is associated wi

27 Acute graft-versus-host disease (aGVHD) is still a major

28 Acute graft-versus-host disease (aGVHD) is the leading c

29 Acute graft-versus-host disease (aGVHD) is the main comp

30 Acute graft-versus-host disease (aGVHD) is the most comm

31 Acute graft-versus-host disease (aGVHD) is the primary l

32 Grades II to IV acute graft-versus-host disease (aGvHD) occurred in 31%.

33 Development of acute graft-versus-host disease (aGVHD) predisposes to c

34 ty and mortality from clinically significant acute graft-versus-host disease (aGVHD) remains a limita

35 Acute graft-versus-host disease (aGVHD) remains a major

36 Acute graft-versus-host disease (aGVHD) remains a seriou

37 helial adhesion molecule induction in murine acute graft-versus-host disease (aGVHD) revealed unexpec

38 ly reported that dermal papillary vessels in acute graft-versus-host disease (aGVHD) support shear-re

39 The incidence of acute graft-versus-host disease (aGVHD) was compared in

40 OS), cumulative incidence of engraftment and acute graft-versus-host disease (aGVHD) within the first

41 geneic hematopoietic cell transplantation is acute graft-versus-host disease (aGVHD), a devastating c

42 In acute graft-versus-host disease (aGVHD), donor T cells a

43 conditioning (with vs. without irradiation), acute graft-versus-host disease (aGVHD), or chronic graf

44 epithelium and may play a role in triggering acute graft-versus-host disease (aGVHD).

45 em cell transplantation (HSCT) is limited by acute graft-versus-host disease (aGvHD).

46 25 immunotoxin (IT) is a strategy to prevent acute graft-versus-host disease (aGvHD).

47 ed for treatment of autoimmune disorders and acute graft-versus-host disease (aGVHD).

48 CD25+ regulatory T cells (Treg cells) reduce acute graft-versus-host disease (aGvHD).

49 nstitution with complications of relapse and acute graft-versus-host disease (aGVHD).

50 atient mixed lymphocyte reactions (MLRs) and acute graft-versus-host disease (aGVHD).

51 alpha) are implicated in the pathogenesis of acute graft-versus-host disease (aGVHD).

52 ntal --> F1) bone marrow transplant model of acute graft-versus-host disease (aGVHD).

53 xenograft models and efficacy in preventing acute graft-versus-host disease (aGVHD).

54 thymus in mice that had previously developed acute graft-versus-host-disease (aGVHD).

55 ster myeloid and platelet recovery and lower acute graft versus host disease and may reduce the total

56 fied according to the presence or absence of acute graft-versus-host disease and CMV DNA in plasma.

57 suggest a novel mechanism explaining reduced acute graft-versus-host disease and improvement in autoi

58 nuated clinical symptoms in animal models of acute graft-versus-host disease and multiple sclerosis.

59 er transplant-related complications, such as acute graft-versus-host disease and opportunistic infect

60 or CMV reactivation, including patients with acute graft-versus-host disease and those receiving ster

61 One patient developed acute graft-versus-host disease and two chronic graft-ve

62 Forty-six patients developed grade II to IV acute graft-versus-host disease, and 68 developed chroni

63 , whereas infection, veno-occlusive disease, acute graft-versus-host disease, and death were predicte

64 raftment preceded donor myeloid engraftment, acute graft-versus-host disease, and disease regression,

65 One patient (5%) experienced grade 2 acute graft-versus-host disease, and no patients experie

66 of veno-occlusive disease, the occurrence of acute graft-versus-host disease, and survival.

67 malization of renal function, the absence of acute graft-versus-host disease, and the establishment o

68 complications, including death, significant acute graft-versus-host disease, and veno-occlusive dise

69 cumulative incidence of grade II, III, or IV acute graft-versus-host disease at 100 days was 64 perce

70 Active acute graft-versus-host disease at TMA diagnosis was the

71 ith a naive phenotype in patients developing acute graft-versus-host disease, compared with tolerant

72 om a skin biopsy of a patient suffering from acute graft-versus-host disease following sex-mismatched

73 nig and colleagues1 demonstrate in mice that acute graft-versus-host disease (GHVD) results in a mark

74 ity (cytopenias) was reported in 4 patients, acute graft-versus-host disease grade 1 in 2, grade 2 in

75 Acute graft-versus-host disease (grade II, III, or IV) d

76 Day 100 cumulative incidences of acute graft-versus-host disease grades B to D and C to D

77 Acute graft-versus-host disease grades II to III occurre

78 Seven patients developed acute graft versus host disease (GVHD) (5 grade I-II, 2

79 cific cytotoxic T cells in a murine model of acute graft versus host disease (GVHD) and enhanced the

80 Lower incidence and severity of acute graft versus host disease (GVHD) has been observed

81 ally for the high morbidity and mortality of acute graft versus host disease (GVHD), however, only fe

82 ich they influence disease processes such as acute graft versus host disease (GVHD), which is the mai

83 fference in the incidence of grades II to IV acute graft versus host disease (GVHD).

84 sis was greater in patients with grade II-IV acute graft-versus-host disease (GVHD) (33.9% +/- 11.3%)

85 V (60% vs 24%, P = .01) and grades III to IV acute graft-versus-host disease (GVHD) (47% vs 14%, P =

86 Complications of DLI included acute graft-versus-host disease (GVHD) (60%; 95% CI, 51.

87 ce of neutrophil recovery at day 60 was 91%, acute graft-versus-host disease (GVHD) (grade II-IV) at

88 associated with an increased probability of acute graft-versus-host disease (GVHD) (P = .02).

89 Acute graft-versus-host disease (GVHD) afflicts as much

90 10RB) gene with development of grades III-IV acute graft-versus-host disease (GVHD) after allogeneic

91 (BMT) recipients are at heightened risk for acute graft-versus-host disease (GVHD) after allogeneic

92 ompatibility antigen HA-1 is associated with acute graft-versus-host disease (GVHD) after allogeneic

93 lls (DC) are important in the development of acute graft-versus-host disease (GVHD) after allogeneic

94 us antithymocyte serum protects mice against acute graft-versus-host disease (GVHD) after hematopoiet

95 of methotrexate (MTX) for the prevention of acute graft-versus-host disease (GVHD) after marrow tran

96 rriage correlates with increased severity of acute graft-versus-host disease (GVHD) after matched unr

97 tat) is safe and results in low incidence of acute graft-versus-host disease (GVHD) after reduced-int

98 Eight patients experienced grade I/II acute graft-versus-host disease (GVHD) after transplanta

99 The incidence and severity of acute graft-versus-host disease (GVHD) after UCB transpl

100 o percent of patients developed grade 2 to 4 acute graft-versus-host disease (GVHD) and 74% extensive

101 the recipient is associated with less severe acute graft-versus-host disease (GVHD) and a lower risk

102 f T-bet and IFN-gamma in T cell responses in acute graft-versus-host disease (GVHD) and found that T-

103 factor, was tested for potential benefits on acute graft-versus-host disease (GVHD) and hematopoietic

104 There exists a strong association between acute graft-versus-host disease (GVHD) and IPS, and bron

105 Acute graft-versus-host disease (GVHD) and leukemic rela

106 Acute graft-versus-host disease (GVHD) and leukemic rela

107 Acute graft-versus-host disease (GVHD) and leukemic rela

108 0, SCD) had slower neutrophil recovery, less acute graft-versus-host disease (GVHD) and none had exte

109 The 6-month probabilities of grade 3 or 4 acute graft-versus-host disease (GVHD) and nonrelapse mo

110 prognostic information about development of acute graft-versus-host disease (GVHD) and subsequent mo

111 , Cav-1(-/-)donor T cells caused less severe acute graft-versus-host disease (GVHD) and yielded highe

112 Algorithms for grading acute graft-versus-host disease (GVHD) are inaccurate in

113 ates, kinetics of engraftment, toxicity, and acute graft-versus-host disease (GVHD) associated with a

114 The probability of grade II to IV acute graft-versus-host disease (GVHD) at 100 days was 3

115 The incidence of grade II-IV acute graft-versus-host disease (GVHD) at 100 days was 9

116 Cumulative incidences of grades 3 to 4 acute graft-versus-host disease (GVHD) at 6 months were

117 Acute graft-versus-host disease (GVHD) causes substantia

118 e alloantigen-driven parent-into F1 model of acute graft-versus-host disease (GVHD) characterized by

119 t 4-fold lower in patients with grade 2 to 4 acute graft-versus-host disease (GVHD) compared with pat

120 Acute graft-versus-host disease (GVHD) complicated UDLI

121 Of these 11 patients, 3 had acute graft-versus-host disease (GVHD) confined to the g

122 Acute graft-versus-host disease (GVHD) considerably limi

123 Acute graft-versus-host disease (GVHD) developed in 18 p

124 Grade III/IV acute graft-versus-host disease (GVHD) developed in 33%

125 Acute graft-versus-host disease (GVHD) developed in 37%

126 o 100 in patients in whom grade 2 or greater acute graft-versus-host disease (GVHD) developed.

127 er induction chemotherapy and the absence of acute graft-versus-host disease (GVHD) development follo

128 10-fold higher dose of transplanted T cells, acute graft-versus-host disease (GVHD) does not develop

129 Five of 9 transplant recipients experienced acute graft-versus-host disease (GVHD) following aNK-DLI

130 The probability of grade II-III acute graft-versus-host disease (GVHD) for all patients

131 Risks of acute graft-versus-host disease (GVHD) grade 2 to 4 (haz

132 Cumulative incidence (day +90) of acute graft-versus-host disease (GVHD) grade 2-4 was 21%

133 Acute graft-versus-host disease (GvHD) grade II to IV oc

134 Acute graft-versus-host disease (GVHD) grades 2 through

135 Acute graft-versus-host disease (GVHD) grades 2-4 was mo

136 DC was associated with acute graft-versus-host disease (GVHD) grades II to IV f

137 Acute graft-versus-host disease (GVHD) grades II to IV w

138 Treatment of acute graft-versus-host disease (GVHD) has evolved from

139 Treatment for steroid-resistant acute graft-versus-host disease (GVHD) has had limited s

140 nal role of Th17 cells in the development of acute graft-versus-host disease (GVHD) has not been well

141 cs and graft composition as risk factors for acute graft-versus-host disease (GVHD) in 160 adult reci

142 as second-line therapy for the treatment of acute graft-versus-host disease (GVHD) in 21 patients (1

143 ood, Shah et al describe the onset of severe acute graft-versus-host disease (GVHD) in 5 of 9 patient

144 nterleukin-18 (IL-18) regulates experimental acute graft-versus-host disease (GVHD) in a Fas-dependen

145 rrow transplantation (BMT) markedly inhibits acute graft-versus-host disease (GVHD) in a fully major

146 bone marrow transplantation (BMT) attenuates acute graft-versus-host disease (GVHD) in a lethally irr

147 O T cells also mediated accelerated onset of acute graft-versus-host disease (GVHD) in a murine model

148 To prevent the development of acute graft-versus-host disease (GVHD) in lethally irrad

149 ory T cells (Tregs) has been used to prevent acute graft-versus-host disease (GVHD) in mice and has s

150 f bone marrow transplantation (BMT) inhibits acute graft-versus-host disease (GVHD) in mice.

151 itioning markedly decreased the mortality of acute graft-versus-host disease (GVHD) in severe combine

152 in vitro and whether those cells can inhibit acute graft-versus-host disease (GVHD) in vivo upon adop

153 Acute graft-versus-host disease (GVHD) increased the ris

154 Acute graft-versus-host disease (GVHD) is a common compl

155 Acute graft-versus-host disease (GvHD) is a complex proc

156 Acute graft-versus-host disease (GVHD) is a considerable

157 Acute graft-versus-host disease (GvHD) is a life-threate

158 Acute graft-versus-host disease (GvHD) is a major cause

159 Acute graft-versus-host disease (GVHD) is a major compli

160 Acute graft-versus-host disease (GvHD) is a major compli

161 Acute graft-versus-host disease (GvHD) is a major compli

162 Acute graft-versus-host disease (GvHD) is a serious comp

163 Acute graft-versus-host disease (GvHD) is an uncommon bu

164 revious experimental studies have shown that acute graft-versus-host disease (GVHD) is associated wit

165 The standard initial therapy for acute graft-versus-host disease (GVHD) is corticosteroid

166 SP) and methotrexate (MTX), the incidence of acute graft-versus-host disease (GVHD) is greater than 7

167 The risk of acute graft-versus-host disease (GVHD) is higher after a

168 Acute graft-versus-host disease (GVHD) is induced by all

169 an important secondary lymphoid organ where acute graft-versus-host disease (GVHD) is initiated by d

170 complication of solid organ transplantation, acute graft-versus-host disease (GVHD) is most associate

171 reased numbers of T cells in the PBSC graft, acute graft-versus-host disease (GVHD) is not increased.

172 Acute graft-versus-host disease (GVHD) is the primary li

173 Acute graft-versus-host disease (GVHD) is thought to be

174 Acute graft-versus-host disease (GVHD) is thought to der

175 nsplantation (BMT), but its association with acute graft-versus-host disease (GVHD) is unclear.

176 Morbidity from acute graft-versus-host disease (GVHD) limits the succes

177 Acute graft-versus-host disease (GVHD) limits the succes

178 tivated lymphocytes in patients with ongoing acute graft-versus-host disease (GVHD) might ameliorate

179 vivo TIP had a protective effect in a mouse acute graft-versus-host disease (GVHD) model.

180 Acute graft-versus-host disease (GVHD) occurred in 11 (1

181 Grade 3 to 4 acute graft-versus-host disease (GVHD) occurred in 20% o

182 Grades II to IV acute graft-versus-host disease (GVHD) occurred in 41% o

183 Grades II to III acute graft-versus-host disease (GVHD) occurred in 47% o

184 Acute graft-versus-host disease (GVHD) occurred in four

185 Grades 2-4 acute graft-versus-host disease (GVHD) occurs in approxi

186 Acute graft-versus-host disease (GVHD) occurs less frequ

187 The relative risk (RR) of acute graft-versus-host disease (GVHD) of grades II to I

188 Acute graft-versus-host disease (GVHD) of the gastrointe

189 ssociations between MPA pharmacokinetics and acute graft-versus-host disease (GVHD) or relapse.

190 g trial, 27 patients with steroid-refractory acute graft-versus-host disease (GVHD) received ABX-CBL

191 Acute graft-versus-host disease (GVHD) remains a barrier

192 sttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major c

193 Acute graft-versus-host disease (GVHD) remains a signifi

194 Acute graft-versus-host disease (GVHD) remains a signifi

195 Treatment of steroid-resistant acute graft-versus-host disease (GVHD) remains an unmet

196 Infections and acute graft-versus-host disease (GvHD) represent major c

197 Acute graft-versus-host disease (GVHD) results from the

198 on, specifically whether prophylaxis through acute graft-versus-host disease (GVHD) results in improv

199 Acute graft-versus-host disease (GVHD) significantly lim

200 ciating graft-versus-tumor (GVT) effect from acute graft-versus-host disease (GVHD) still remains a g

201 nal signature of T cells during breakthrough acute graft-versus-host disease (GVHD) that occurs in th

202 The optimal primary endpoint for acute graft-versus-host disease (GVHD) therapeutic trial

203 omarkers are associated with the response of acute graft-versus-host disease (GVHD) to therapy after

204 Grades II to IV acute graft-versus-host disease (GVHD) was associated wi

205 Acute graft-versus-host disease (GVHD) was more likely t

206 Further, the incidence of grades III to IV acute graft-versus-host disease (GVHD) was significantly

207 Grade 2 to 4 acute graft-versus-host disease (GVHD) was significantly

208 cumulative incidences of grades 2, 3, and 4 acute graft-versus-host disease (GVHD) were 38%, 9%, and

209 , 17 patients with glucocorticoid-refractory acute graft-versus-host disease (GVHD) were enrolled in

210 ere confirmed in vivo using a mouse model of acute graft-versus-host disease (GVHD) wherein host DCs

211 We hypothesized that initial treatment of acute graft-versus-host disease (GVHD) with low-dose glu

212 ation (BMT) resulted in marked inhibition of acute graft-versus-host disease (GVHD) with retention of

213 topoietic cell transplantation is limited by acute graft-versus-host disease (GvHD), a severe complic

214 nces of neutrophil engraftment, grades II-IV acute graft-versus-host disease (GVHD), and chronic GVHD

215 ll IFN-gamma production correlated with more acute graft-versus-host disease (GVHD), and decreased KI

216 s at the time of transplant, the presence of acute graft-versus-host disease (GVHD), and type of cond

217 teroids are the accepted primary therapy for acute graft-versus-host disease (GVHD), but durable resp

218 , with primary risk factors including severe acute graft-versus-host disease (GVHD), chronic extensiv

219 f HLA-A, B, or C, on the risks for grade 3-4 acute graft-versus-host disease (GVHD), chronic GVHD, tr

220 in improving engraftment without increasing acute graft-versus-host disease (GVHD), despite much lar

221 The incidences of grade 2 to 4 acute graft-versus-host disease (GVHD), grade 3 and 4 ac

222 ortant causes of diarrhea after HSCT include acute graft-versus-host disease (GVHD), infections, and

223 In acute graft-versus-host disease (GVHD), naive donor CD4(

224 an matched controls to have had grade 2 to 4 acute graft-versus-host disease (GVHD), required therapy

225 ointestinal tract are major target organs of acute graft-versus-host disease (GVHD), the major compli

226 KIR-L mismatch had no effect on grade III-IV acute graft-versus-host disease (GVHD), transplantation-

227 responses of allogeneic BM donors may affect acute graft-versus-host disease (GVHD), we investigated

228 ients developed grade C (n = 4) or D (n = 1) acute graft-versus-host disease (GVHD), with only one at

229 y reported that interleukin (IL)-12 prevents acute graft-versus-host disease (GVHD)-induced mortality

230 s play a critical role in pathophysiology of acute graft-versus-host disease (GVHD).

231 No validated biomarkers exist for acute graft-versus-host disease (GVHD).

232 eneic stem cell transplantation resulting in acute graft-versus-host disease (GVHD).

233 titox in 30 patients with steroid refractory acute graft-versus-host disease (GVHD).

234 logeneic BMT without DLI and 5 patients with acute graft-versus-host disease (GVHD).

235 observed between groups in the incidence of acute graft-versus-host disease (GVHD).

236 mmune disease that is indistinguishable from acute graft-versus-host disease (GVHD).

237 m cell transplantation can be complicated by acute graft-versus-host disease (GVHD).

238 tal models of inflammatory bowel disease and acute graft-versus-host disease (GVHD).

239 ed with increased incidence of grades III-IV acute graft-versus-host disease (GVHD).

240 IL-18 is elevated during acute graft-versus-host disease (GVHD).

241 (RR = 43.2) for prophylaxis or treatment of acute graft-versus-host disease (GVHD).

242 ays -4 to +45 to prevent graft rejection and acute graft-versus-host disease (GVHD).

243 aft rejection and no cases of grade II to IV acute graft-versus-host disease (GVHD).

244 ransplant recipients with steroid-refractory acute graft-versus-host disease (GVHD).

245 bone marrow and blood did not produce severe acute graft-versus-host disease (GVHD).

246 ell transplantation (allo-HCT) is limited by acute graft-versus-host disease (GVHD).

247 disorders but carries a significant risk of acute graft-versus-host disease (GVHD).

248 vs steroids/placebo to treat newly diagnosed acute graft-versus-host disease (GVHD).

249 influenza virus infection and in a model of acute graft-versus-host disease (GVHD).

250 of Paneth cell loss in gastrointestinal (GI) acute graft-versus-host disease (GVHD).

251 HSCT, broad-spectrum antimicrobial use, and acute graft-versus-host disease (GVHD; adjusted odds rat

252 Thirty-eight percent of patients developed acute graft-versus-host disease (GVHD; grade II in all b

253 IR3DS1 was associated with lower-grade II-IV acute graft-versus-host disease (GVHD; odds ratio = 0.71

254 an increased risk of severe (grades III-IV) acute graft-versus-host disease (GVHD; relative risk [RR

255 icted a greater risk of developing grade 3-4 acute graft-versus-host disease (GVHD; RR = 1.58, 95% CI

256 The association of gB types with acute graft-versus-host-disease (GVHD) and death related

257 In hematopoietic stem cell transplantation, acute graft-versus-host-disease (GVHD) is caused by an a

258 alyzed with respect to tempo of engraftment, acute graft-versus-host-disease (GVHD), clinical extensi

259 phyrin (CoPP) can prevent the development of acute graft-versus-host-disease (GVHD).

260 y; acute toxicity (veno-occlusive disease or acute graft versus-host disease [GvHD]); chronic GvHD; o

261 G was associated with decreased incidence of acute graft-versus-host disease (hazard ratio [HR], 0.31

262 associated with an increased risk of severe acute graft-versus-host disease (HR = 1.43, P = 0.730).

263 d mortality (HR = 1.54, 1.54), and grade 3-4 acute graft-versus-host disease (HR = 1.49, 1.77) compar

264 The CI of acute graft-versus-host disease II to IV was 32.3% after

265 neutrophil and platelets recovery and lower acute graft versus host disease (II-IV) (P<0.01).

266 ions were present in 50% of the patients and acute graft-versus-host disease in 33%.

267 and Treg cells in association with clinical acute graft-versus-host disease in allogeneic hematopoie

268 fectively suppress inflammatory responses in acute graft-versus-host disease in humans and in a numbe

269 mAb against PD-1H, which strikingly prevents acute graft-versus-host disease in semi- and fully allog

270 idence interval, 1.84-31.7), controlling for acute graft-versus-host disease, in 109 patients with Ph

271 h in vitro and in vivo, including inhibiting acute graft-versus-host disease induced by allogeneic CD

272 he role of IL-18 in three disease processes (acute graft-versus-host disease, insulin-dependent diabe

273 Acute graft-versus-host disease is a complication that a

274 Acute graft-versus-host disease is one of the commonest

275 impact in vivo alloresponses using a severe acute graft versus host disease model.

276 bit potent regulatory function in vivo in an acute graft-versus-host disease model.

277 Five patients had grade II or grade III acute graft-versus-host disease; none had extensive chro

278 Acute graft-versus-host disease of grade III or IV sever

279 required no platelet or RBC transfusion, and acute graft-versus-host disease of greater than grade 2

280 ppeared to be independent of CMV viral load, acute graft-versus-host disease, or ganciclovir-associat

281 matched HCT, myeloablative conditioning, and acute graft-versus-host disease (P values < .01).

282 aper, we show human CD4/CD8 double-positive, acute graft-versus-host disease-protective, minor H Ag-s

283 Acute graft-versus-host disease rates were similar betwe

284 survival or in the incidence or severity of acute graft-versus-host disease regardless of exposure t

285 Grade II to IV acute graft-versus-host disease related to steroid treat

286 Grade 2 to 4 acute graft-versus-host disease risks were higher after

287 graftment, and decreased incidence of severe acute graft-versus-host disease (RR: 0.6, CI: 0.4 to 0.9

288 Therapy for steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains subop

289 Only 1 patient developed skin-only acute graft-versus-host disease that resolved without an

290 the armamentarium against steroid-refractory acute graft-versus-host disease, the prognosis of this e

291 History of grade II-IV acute graft versus host disease was associated with an i

292 The probability of grade 2-4 and 3-4 acute graft-versus-host disease was 0.49 (95% CI, 0.38-0

293 The cumulative incidence of grade III to IV acute graft-versus-host disease was 36% by D+100.

294 Acute graft-versus-host disease was associated with fewe

295 The risk of grades III-IV acute graft-versus-host disease was highest with class I

296 serum level of cyclosporine, infections, and acute graft versus host disease were compared statistica

297 abilities of nonrelapse mortality and severe acute graft-versus-host disease were 8% and 4%.

298 mia or myelodys-plastic syndrome, and severe acute graft-versus-host disease were associated with sig

299 er risks of LONIPC, but age, graft type, and acute graft-versus-host disease were not identified as r

300 Survival, engraftment, and acute graft-versus-host disease were studied.